Revenue Breakdown
Composition ()
No data
Revenue Streams
TG Therapeutics Inc (TGTX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Total product revenue, net, accounting for 98.5% of total sales, equivalent to $159.32M. Another important revenue stream is License, milestone, royalty and other revenue. Understanding this composition is critical for investors evaluating how TGTX navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, TG Therapeutics Inc maintains a gross margin of 80.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 26.22%, while the net margin is 11.96%. These profitability ratios, combined with a Return on Equity (ROE) of 102.75%, provide a clear picture of how effectively TGTX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TGTX competes directly with industry leaders such as ALKS and FOLD. With a market capitalization of $4.69B, it holds a significant position in the sector. When comparing efficiency, TGTX's gross margin of 80.19% stands against ALKS's 87.98% and FOLD's 84.64%. Such benchmarking helps identify whether TG Therapeutics Inc is trading at a premium or discount relative to its financial performance.
